Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819390 · ClinicalTrials.gov registry record · Phase 2
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
A Phase 2 study of HIV Infections, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 15
- Study locations
NCT00819390 is a Phase 2 study of HIV Infections that has completed, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 70 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (84% lower). The trial reports 15 study locations across 12 states.
The verdict
NCT00819390, a Phase 2 study of HIV Infections, has completed, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 15
- Study locations
Study Summary
HIV is characterized by frequent immune system activation. Early in the course of infection the body establishes an immune activation "set point" related to the amount of HIV in the blood stream. This set point affects the rate of CD4 cell loss. Without CD4 cells, or with very low levels of CD4 cells, the body cannot fight off illness. This is known as immunodeficiency. If left untreated HIV can lead to extreme immunodeficiency and AIDS. Evidence suggests that by decreasing the rate of immune system activation, immune deficiency progression could be prevented. The purpose of this study is to learn how well chloroquine can reduce the level of immune activation and to test the safety and tolerance of chloroquine in people infected with HIV.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Chloroquine
Study Locations (15)
Ohio
- Univ. of Cincinnati CRS (2401) - Cincinnati
- Case CRS (2501) - Cleveland
- MetroHealth CRS (2503) - Cleveland
Pennsylvania
- Hosp. of the Univ. of Pennsylvania CRS (6201) - Philadelphia
- Pittsburgh CRS (1001) - Pittsburgh
Alabama
- Alabama Therapeutics CRS (5801) - Birmingham
California
- Ucsd, Avrc Crs (701) - San Diego
Colorado
- University of Colorado Hospital CRS (6101) - Aurora
District of Columbia
- Georgetown University CRS (GU CRS) (1008) - Washington D.C.
Maryland
- Johns Hopkins Adult AIDS CRS (201) - Baltimore
Massachusetts
- Massachusetts General Hospital ACTG CRS (101) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00819390
The ClinicalTrials.gov registry entry for NCT00819390 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (84% lower). The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00819390 reports 15 study locations spanning 12 distinct geographic areas - top geographies include Ohio, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT00819390 about?
NCT00819390 is a clinical study titled "Chloroquine for Reducing Immune Activation in HIV- Infected Individuals". HIV is characterized by frequent immune system activation. Early in the course of infection the body establishes an immune activation "set point" related to the amount of HIV in the blood stream. This set point affects the rate of CD4 cell loss. Without CD4 cells, or with very low levels of CD4 cell...
What is the current status of trial NCT00819390?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2009-03. Estimated completion is 2013-05.
What conditions does trial NCT00819390 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00819390?
The interventions under investigation include: Placebo (DRUG), Chloroquine (DRUG).
Who is sponsoring clinical trial NCT00819390?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00819390 being conducted?
This trial has 15 study locations across Alabama, California, Colorado, District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.